Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-8371 in Advanced Malignancies
NCT06150664Phase 1Recruiting
- Sponsor
- Compass Therapeutics, Inc.
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CTX-8371 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL) and 2 more (2 cohorts), sponsored by Compass Therapeutics, Inc. Primary endpoints: Safety and tolerability of CTX-8371 up to 2 years and Recommended Phase 2 Dose at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
CTX-8371
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)Hodgkin lymphoma (HL)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT06150664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150664.